PPD increases focus on vaccines and biologics
PPD has added capabilities at the facility acquired from Merck & Co and improved integration of other sites to create its Vaccines & Biologics Center of Excellence, a single provider of multiple laboratory services.
IRL and Epichem partner to serve Australasian market
IRL and Epichem have entered into a strategic alliance to provide the Australasian pharma market with services from drug discovery through to cGMP production.
Affinity, JSW partnership expands reach & services
Affinity Life Sciences and JSW Life Sciences have entered into a strategic partnership to bolster their contract research and manufacturing capabilities.
Pall teams with Sotax on filters; reports biopharma biz strong in Q2
Industrial filtration specialist Pall and testing firm Sotax say their new co-marketing deal is only first stage of planned pharmaceutical industry certification solutions partnership.
NexACT shows preclinical SR potential
CRO NexMed says new data from preclinical trials show that its NexACT delivery technology can act as a sustained release “depot” for drugs like insulin and taxol.
Millipore launches Milliflex Quantum for rapid microbial detection
Millipore has expanded its microbial detection offering with Milliflex Quantum which, it says, enables manufacturers to respond to contamination issues earlier in the drug and vaccine production process.
Pfizer and Tekirma team on siRNA delivery
US drug giant Pfizer will assess Tekimra Pharmaceuticals’s stable nucleic acid-lipid particle (SNALP) platform for the delivery of siRNA drugs.
Compugen creates system to predict peptide delivery
Compugen has developed a computer-based, in silico system which can assist drug delivery research by identifying peptides that have the potential to penetrate cell membranes.
Sigma adds big name small molecules to portfolio in Pfizer deal
Drug researchers will have greater access to some top selling molecules, including currently patented compounds atorvastatin, sildenafil and celecoxib, thanks to Sigma Aldrich’s new bioactives deal with US drug major Pfizer.
China to build ‘one of largest biologics CMOs in Asia’
The Chinese government is supporting a $100m (€73m) project to build a contract biologics production facility in Beijing, which, by some measures, would be the largest in Asia.
Pharmadule providing modular biotech plant to Silcor
Pharmadule AB is creating a complete modular biologics production facility, which will be 80 per cent completed in its workshop before delivery, to Lithuania-based Silcor Biotech by 2011.
Glycos scales up sustainable lactic acid production
Glycos Biotechnologies has produced lactic acid in a pilot plant using its sustainable technique, successfully scaling up from a laboratory setting to provide an alternate source for the chiral synthon.
Wacker opens €18m expansion of biologics site
Wacker Chemie AG has expanded its biologics production facility, adding GMP manufacturing capacity and a process development building in response to customer demand.
Synthemax cuts hESC production cost say Geron and Corning
New Synthemax synthetic growth matrix promises improved scalability for large-scale hESC production which, say developers Geron and Corning, will cut cost of cell therapy manufacture.
The US FDA wants to boost the production of cell-based viral vaccines and says new guidance will help manufacturers.